Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...

Compared to its lackluster second quarter performance, Merck rallied somewhat in the third quarter of 2025. Revenue and ...

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid ...

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Merck & Co beat third-quarter (3Q) sales expectations on strong results from its pneumonia vaccine as the company works to ...

Merck reported Q3 2025 revenue of $17.3 billion and adjusted EPS of $2.58, both above expectations, and raised its full-year ...

Q3 earnings beat estimates, but shares dip as 2025 sales outlook narrows. Get key highlights and pharma market insights.